3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
87
Lymphoma, Non-Hodgkin
72
Lymphoma
63
Lymphoma, Follicular
59
Lymphoma, Mantle-Cell
58
Lymphoma, Large B-Cell, Diffuse
40
Hodgkin Disease
32
Lymphoma, B-Cell, Marginal Zone
28
Recurrence
25
Lymphoma, B-Cell
19
Leukemia
17
Waldenstrom Macroglobulinemia
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Neoplasms
11
Lymphoma, T-Cell
7
Burkitt Lymphoma
7
Lymphoma, T-Cell, Peripheral
6
Leukemia, Myeloid, Acute
6
Leukemia, B-Cell
6
Sezary Syndrome
5
Mycosis Fungoides
5
Multiple Myeloma
5
Immune System Diseases
5
Myelodysplastic Syndromes
4
Lymphoma, T-Cell, Cutaneous
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, Extranodal NK-T-Cell
4
Lymphatic Diseases
4
Immunoblastic Lymphadenopathy
4
Interventions
pembrolizumab
5
Gemcitabine
1
Brentuximab Vedotin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Bendamustine Hydrochloride
×
Lymphoid
×
Clear all
NCT05508867
2026-01-20
MK-4280A-008
Merck Sharp & Dohme LLC
Phase 2
Completed
203 enrolled